The Influence of Heart Rate Reduction Upon Central Arterial Pressure in Younger and Older Healthy Individuals

Status

Withdrawn

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01029223

Enrollment

Registered

2009-12-09

Start date

2008-10-31

Completion date

2011-12-31

Last updated

2011-11-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Pressure

Brief summary

The purpose of this study is to determine the effect of slowing heart rate upon both central and peripheral blood pressures using a medication called Ivabradine which slows heart rate without affecting heart contraction, and to compare the effects of ivabradine to a traditional blood pressure lowering medication called metoprolol (which is a beta-blocker).

Interventions

DRUGivabradine

DRUGmetoprolol

DRUGplacebo

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

BASIC_SCIENCE

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

MALE

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Aged 18 - 25 years OR * Aged \> 60 years

Exclusion criteria

* Chronic disease * Unable to give informed consent * Treated or untreated systemic arterial hypertension (SBP \> 160 mmHg and/or DBP \> 90 mmHg) * Resting bradycardia (heart rate \< 60 beats/minute) * Pregnancy or active lactation

Design outcomes

Primary

Measure	Time frame
central and peripheral arterial and pulse wave velocity	baseline, and 4 hours following the administration of placebo, metoprolol or ivabradine.

Secondary

Measure	Time frame
Central pulse pressure	Baseline measurements of central and peripheral arterial and pulse wave velocity will be made at baseline, and 4 hours following the administration of either placebo, metoprolol or ivabradine.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026